“…In light of recent reports indicating that posttranslational modifications of HMGB1 modulate its bioactivity, we used proteomic mass spectrometry (MS) and tandem mass spectrometry (MS/MS) (39) to identify the presence of HMGB1 posttranslational modifications in the serum of acetaminophen-treated mice and to assign them to specific cellular sources. We observed the presence of 4 distinct and amplifies injury in vivo, focusing on Toll-like receptor 4 (TLR4) and the receptor for advanced glycation end-products (RAGE) as the best-established HMGB1 receptors (41).…”
Section: Hmgb1 Does Not Mediate Lps-induced Lethal Shockmentioning
“…In light of recent reports indicating that posttranslational modifications of HMGB1 modulate its bioactivity, we used proteomic mass spectrometry (MS) and tandem mass spectrometry (MS/MS) (39) to identify the presence of HMGB1 posttranslational modifications in the serum of acetaminophen-treated mice and to assign them to specific cellular sources. We observed the presence of 4 distinct and amplifies injury in vivo, focusing on Toll-like receptor 4 (TLR4) and the receptor for advanced glycation end-products (RAGE) as the best-established HMGB1 receptors (41).…”
Section: Hmgb1 Does Not Mediate Lps-induced Lethal Shockmentioning
“…Alcoholic fatty liver is the earliest and most common response of the liver to alcohol and may be a precursor of more severe forms of liver injury, like steatohepatitis, progressive fibrosis, cirrhosis, and hepatocellular carcinoma (4,49). Although the pathogenesis and diagnosis are different between nonalcoholic and alcoholic fatty liver disease, excessive triglyceride accumulation in the liver induced by activation of lipogenesis is their common feature.…”
Background: Hepatic steatosis is an increasing health concern associated with metabolic syndrome. Results: RGC-32 deficiency protects mice from HFD-and ethanol-induced hepatic steatosis by decreasing hepatic lipogenic gene expression. Conclusion: RGC-32 is a novel regulator for hepatic lipogenesis. Significance: RGC-32 may be a novel target for treating hepatic steatosis.
“…In mouse models for alcoholic hepatitis, the inhibition of DAMPs was shown to decrease proinflammatory cytokines, the degree of liver inflammation, and liver steatosis (29,30). The identification of DAMPs and further determination of the effect of pharmacologic DAMPs inhibition might guide future immunotherapeutic intervention in order to limit the inflammatory response and to potentially improve the outcome.…”
Section: Original Article Jaruvongvanich Et Al Sirs In Alcoholic Hepmentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.